The Forum will feature 20-minute presentations (including Q&A) from a curated group of innovative start-up companies, each carefully vetted through our screening process. Attendees will also enjoy updates from select past presenting companies as they share their latest milestones.
Auctus Surgical is solving scoliosis with a minimally invasive implant that preserves motion and grows with the child. These "braces" for the spine are designed to address the $10B worldwide deformity market with applications for children and adults. Management has 90 years combined in the industry and $1.75B in investor value creation from previous exits. They believe that children with scoliosis should not be limited and deserve the same active healthy life as their peers.
When one disposes of an Amazon box, the cardboard will degrade, but the adhesive will remain in the landfill for over 30 years. BioBond solves this $5B problem.
Elucidate Bio is a disruptive AI/Cell Biology startup that is already creating cancer breakthroughs. Validated by Pharma experts without requiring FDA approval, they have attractive revenues that bring them close to break-even at seed stage.
Northern Vascular has developed a light-activated gel and delivery system to treat neurovascular disorders, including aneurysms, tumours, and beyond. The gel is non-toxic, water soluble, and allows clinicians greater control over when, where, and how embolization occurs through exposure to light, with the potential to disrupt a $5.5B market.
The information ecosystem is being rewired. AllSides is doing it with integrity. Their technologies free people from manipulative, biased information systems in tech, media, government, and education to reveal the full picture. AllSides is raising a $10MM Series A to become the global standard for information integrity.
QSM is disrupting how diagnostic testing is done for pets. QSM's revolutionary products improve outcomes, save time, and increase revenues for veterinarians while offering more accessibility and unprecedented convenience for pet parents.
Ordaos Bio’s lab-in-the-loop AI platform designs novel biologics, validated by successful projects with top pharma. Their 5-day "lab-in-the-loop" cycle promises better drugs to patients faster and more reliably than alternatives. With $40M+ in near-term license potential, they are raising a $7M bridge to advance lead assets through in vivo studies.
The AI-powered flow cytometry standard transforming biomarker discovery, unlocking a $5.7 billion market. Interro IQ's Universal Immunophenotyping Screen combines AI-enabled flow cytometry with standardization to rapidly identify clinically useful biomarkers. Disease-agnostic and scalable, the UIS delivers results in weeks, making equivalent 2 year timelines feasible in 2-8 weeks.